EDITION:

Journal Of Cellular And Molecular Medicine Publish Academic Paper On Effect Of ArtemiC In Patients With COVID-19

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of phytomedicines, has had a peer reviewed paper into the Effect of ArtemiC in patients with COVID-19 published in the Journal of Cellular and Molecular Medicine.

Key Highlights:

  • Journal of Cellular and Molecular Medicine have published a study into the effect of MGC Pharma’s proprietary product ArtemiC™ in patients with Covid-19.
  • The Phase II prospective study is peer reviewed and is available for all to read
  • This is the first clinical study addressing the safety and tolerability of ArtemiC oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients.
  • These findings suggest that ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19.

The Phase II prospective study of 50 patients all with COVID-19 concludes that “ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19, and bears great promise for COVID-19 patients, particularly in those with comorbidities.”

This is the first clinical study addressing the safety and tolerability of ArtemiC™ oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients and the first scientific article published on ArtemiC™.

The article is open access, and can be read in the Journal of Cellular and Molecular Medicine at the link below: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17337

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?